PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY

Detalles Bibliográficos
Autores principales: Sehn, L. H., Avivi, I., Brody, J., Yoon, D. H., Elliott, B. M., Siddani, S. R., Bai, Y., Parikh, A., Seliem, M. M., Dinh, M. H., Skarbnik, A. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431595/
http://dx.doi.org/10.1097/01.HS9.0000851364.83658.ec

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431595/
http://dx.doi.org/10.1097/01.HS9.0000851364.83658.ec

Ejemplares similares